[1] American Diabetes Association. Clinical practice recommendations 2005[J]. Diabetes Care, 2005, 28(Suppl 1): S1-S79. [2] AL-MUTAIRI N, EASSA B I, AL-RQOBAH D A. Clinical and mycologic characteristics of onychomycosis in diabetic patients[J]. Acta Dermatovenerol Croat, 2010, 18(2): 84-91. [3] AMEEN M, LEAR J T, MADAN V, et al. British Association of Dermatologists’ guidelines for the management of onychomycosis 2014[J]. Br J Dermatol, 2014, 171(5): 937-958. [4] 甲真菌病指南专家工作组. 中国甲真菌病诊疗指南(2021年版)[J]. 中国真菌学杂志, 2022, 17(1): 1-7. [5] ZARAA I, DEHAVAY F, RICHERT B. Onychomycosis[J]. Hand Surg Rehabil, 2024, 43(Suppl): 101638. [6] 王妍妮, 朱晓芳. 2型糖尿病合并甲真菌病的流行病学研究进展[J]. 中国真菌学杂志, 2025, 20(2): 213-216. [7] THOMAS J, PETERSON G M, CHRISTENSON J K, et al.Antifungal drug use for onychomycosis[J]. Am J Ther, 2019, 26(3): e388-e396. [8] BAKKER K, APELQVIST J, SCHAPER N C. Practical guidelines on the management and prevention of the diabetic foot 2011[J]. Diabetes Metab Res Rev, 2012, 28(S1): 225-231. [9] 王志稳, 韩舒羽. 护理领域专家共识论文的质量评价要点[J]. 中华护理杂志, 2024, 59(3): 267-270. [10] FOSTER M J, SHURTZ S. Making the Critical Appraisal for Summaries of Evidence (CASE) for evidence-based medicine (EBM): critical appraisal of summaries of evidence[J]. J Med Libr Assoc, 2013, 101(3): 192-198. [11] 谢利民, 王文岳. 《临床指南研究与评价系统Ⅱ》简介[J]. 中西医结合学报, 2012, 10(2): 160-165. [12] SHEA B J, REEVES B C, WELLS G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both[J]. BMJ, 2017, 358: j4008. [13] MCARTHUR A, COOPER A, EDWARDS D, et al. Textual evidence systematic reviews series paper 3: critical appraisal of evidence from narrative, opinion, and policy[J]. JBI Evidence Synthesis, 2025, 23(5):833-839. [14] 陈耀龙, 李幼平, 杜亮, 等. 医学研究中证据分级和推荐强度的演进[J]. 中国循证医学杂志, 2008, 8(2): 127-133. [15] 王春青, 胡雁. JBI证据预分级及证据推荐级别系统(2014版)[J]. 护士进修杂志, 2015, 30(11): 964-967. [16] Ministry of Health Malaysia. Management of Diabetic Foot (Second Edition)[EB/OL]. [2025-06-10]. https://www.acadmed.org.my/CPGdl/QR%20Management%20of%20Diabetic%20Foot%20(2nd%20Ed).pdf. [17] National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management [EB/OL]. (2019-10-11)[2025-06-10]. https://www.nice.org.uk/guidance/ng19. [18] SCHAPER N C, VAN NETTEN J J, APELQVIST J, et al. Practical guidelines on the prevention and management of diabetes-related foot disease (IWGDF 2023 update)[J]. Diabetes Metab Res, 2024, 40(3): e3657. [19] Registered Nurses’ Association of Ontario. Diabetic foot ulcers: Prevention, assessment and management. 3rd ed. [EB/OL]. (2024-10-30)[2025-06-10]. https://rnao.ca/bpg/guidelines/diabetic-foot-ulcer. [20] NENOFF P, REINEL D, MAYSER P, et al.S1 guideline onychomycosis[J]. J Dtsch Dermatol Ges, 2023, 21(6): 678-692. [21] ELY J W, ROSENFELD S, SEABURY STONE M. Diagnosis and management of tinea infections[J]. Am Fam Physician, 2014, 90(10): 702-710. [22] American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes-2024[J]. Diabetes Care, 2024, 47(Suppl 1): S231-S243. [23] 国家老年医学中心, 中华医学会老年医学分会, 中国老年保健协会糖尿病专业委员会. 中国老年糖尿病诊疗指南(2024版)[J]. 协和医学杂志, 2024, 15(4): 771-800. [24] 《中国老年型糖尿病防治临床指南》编写组. 中国老年2型糖尿病防治临床指南(2022年版)[J]. 中国糖尿病杂志, 2022, 30(1): 2-51. [25] 倪青, 王世东, 于秀辰, 等. 糖尿病周围血管病变相关性糖尿病足中西医结合诊疗指南[J]. 中国临床保健杂志, 2025, 28(2): 145-156. [26] 中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 中华糖尿病杂志, 2021, 13(4): 315-409. [27] 谢晓冉, 徐蓉. 糖尿病足发病风险筛查和评估的最佳证据总结[J]. 护理学杂志, 2020, 35(24): 90-93. [28] 罗文静, 李欣仪, 赵楠, 等. 糖尿病足风险筛查的最佳证据总结[J]. 解放军护理杂志, 2021, 38(8): 50-54. [29] 陈欢, 侯朝铭, 高静, 等. 糖尿病患者甲病管理的最佳证据总结[J]. 中国全科医学, 2022, 25(32): 3984-3990. [30] 宋品芳, 周秋红, 白姣姣, 等. 糖尿病周围神经病变患者皮肤保护的最佳证据总结[J]. 上海护理, 2021, 21(12): 25-30. [31] 魏婷, 王静, 胡雁, 等. 社区糖尿病高危足足部管理最佳证据总结及证据可用性评价[J]. 循证护理, 2024, 10(9): 1521-1529. [32] 谢晓冉, 徐蓉. 糖尿病足发病风险预测模型的系统评价[J]. 中华护理杂志, 2021, 56(1): 124-131. [33] 中国中西医结合学会周围血管病专业委员会.中西医结合防治糖尿病足中国专家共识(第1版)[J]. 血管与腔内血管外科杂志, 2019, 5(5): 379-402. [34] RAJAGOPALAN M, INAMADAR A, MITTAL A, et al. Expertconsensus on the management of dermatophytosis in India (ECTODERM India)[J]. BMC Dermatol, 2018, 18(1): 6. [35] 中华护理学会糖尿病护理专业委员会. 糖尿病患者甲病护理的专家共识[J]. 中华护理杂志, 2020, 55(Suppl): 122-127. [36] SOUSA MURO E, SEPULVEDRA GODOY MUNHOZ A A, APARECIDA MANTUANI A P, et al. Evidence for the evaluation of the feet of people with diabetes mellitus[J]. Rev Enferm UFPE, 2018, 12(7): 2021-2030. [37] 上海市康复医学会. 老年糖尿病患者甲病康复护理: T/SRMA 17—2023[S]. 上海: 上海市康复医学会, 2023. [38] MOCHIZUKI T, TSUBOI R, IOZUMI K, et al. Guidelines for the management of dermatomycosis (2019)[J]. J Dermatol, 2020, 47(12): 1343-1373. [39] DE-LA-ROSA-GARIBAY E, ARENAS R, HERRERA-CASTRO M Y, et al. Onychomycosisendonyx: a systematic review[J]. Diseases, 2025, 13(4): 110. [40] GUPTA A K, SIMKOVICH A J, HALL D C. The march against onychomycosis: a systematic review of the sanitization methods for shoes, socks, and textiles[J]. J Am Podiatr Med Assoc, 2022, 112(4): 21-223. [41] TAKEHARA K, OE M, TSUNEMI Y, et al. Factors associated with presence and severity of toenail onychomycosis in patients with diabetes: a cross-sectional study[J]. Int J Nurs Stud, 2011, 48(9): 1101-1108. |